Relevance of Peripheral Cells in CMML
Official title: Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Run by Centre Hospitalier Universitaire de Nice · NCT03280888 · Data updated 2026-11-12
This study looks at how peripheral blood cells relate to chronic myelomonocytic leukemia and how they might help understand the disease in patients being treated at participating centers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Status | Recruiting |
| Started | November 5, 2014 |
| Main results expected | November 5, 2027 |
| Study ends | November 5, 2028 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT03280888 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with CMML who are new to diagnosis or currently undergoing treatment at the participating Clinical Hematology departments.
✕Probably not a fit
Patients without CMML or those not part of the participating centers may not benefit from this observational work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the role of peripheral cells in the pathophysiology of chronic myelomonocytic leukemia (CMML). It leverages patients diagnosed or treated in the Clinical Hematology department at participating sites to explore relevant cellular markers. The aim is to improve understanding of CMML biology where curative options are limited for many patients. No intervention is described; findings may inform future research directions and potential biomarkers. The lead site is CHU de Nice, France.
Why it matters
Potential benefit: Findings could improve understanding of CMML biology and identify biomarkers that help tailor future therapies.
How similar studies have gone: Previous observational work in CMML has contributed to understanding disease biology, but this specific focus on peripheral cells is exploratory and not yet proven to change practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients newly diagnosed or undergoing treatment in the Clinical Hematology department of the participating establishments Exclusion Criteria: * NA
Where it's running
-
CHU de Nice
Nice, France Recruiting
Study contacts
- Study coordinator: Laurence Legros, PH
- Email: legros.l@chu-nice.fr
- Phone: +33 (0)4 92 03 58 41
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose post-transplant cyclophosphamide plus tacrolimus and ruxolitinib to prevent GVHD after myeloablative peripheral blood stem cell transplant
This test sees if adding low-dose post-transplant cyclophosphamide with tacrolimus and ruxolitinib can reduce severe acute graft-versus-host disease in adults receiving myeloablative peripheral blood stem cell transplants for leukemia or myelodysplasia.
-
Momelotinib plus azacitidine for chronic-phase MDS/MPN and chronic neutrophilic leukemia
This trial will test whether adding momelotinib to a standard hypomethylating drug helps adults with chronic-phase MDS/MPN or chronic neutrophilic leukemia control their disease and symptoms.
-
FLAG‑Ida chemotherapy followed by reduced‑intensity total‑body irradiation and donor stem cell transplant for adults 60+ with adverse‑risk AML or other high‑grade myeloid cancers
This trial tests whether FLAG‑Ida chemotherapy given immediately before lower‑intensity total‑body radiation and a donor stem cell transplant can improve outcomes for adults 60 and older with newly diagnosed adverse‑risk acute myeloid leukemia or similar high‑grade myeloid cancers.
-
Testing STX-0712 in patients with advanced blood cancers
This study is testing a new drug called STX-0712 to see if it can help people with advanced blood cancers like chronic myelomonocytic leukemia and acute myeloid leukemia who have run out of other treatment options.
-
Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant
This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.
-
Oral arsenic trioxide plus vitamin C with low-intensity therapy for TP53-mutated AML/MDS/CMML
This trial will test whether taking oral arsenic trioxide with vitamin C plus a low-intensity drug (a hypomethylating agent, with or without venetoclax) helps adults with TP53-mutated AML, MDS, or CMML who are newly diagnosed or have relapsed/refractory disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.